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Introduction: The aim was to evaluate S100A4 protein as a biomarker of disease activity and potential cancer
development in patients with myositis.
Methods: Serum levels of S100A4 were determined in 43 dermatomyositis (DM), 39 polymyositis (PM) and 22
cancer associated myositis (CAM) patients as well as in 77 healthy controls. The associations between S100A4 levels,
inflammation, disease activity, muscle strength and cancer development were evaluated.
Results: All myositis patients had significantly higher serum levels of S100A4 protein compared to healthy controls
(median (IQR): 31.5 (17.4 to 59.5) versus 23.8 (14.5 to 33.7) ng/ml, P <0.05). In patients with PM, serum levels of S100A4
protein were significantly higher than in healthy controls (41.6 (24.2 to 123.1) versus 23.8 (14.5 to 33.7) ng/ml; P <0.001)
as well as in patients with DM (26.7 (11.3 to 47.5) ng/ml; P <0.05). The levels of S100A4 were comparable between
myositis with and without cancer. In all myositis patients, serum S100A4 levels correlated with MYOsitis disease ACTivity
assessment (MYOACT) score (r = 0.34; P = 0.001), constitutional (r = 0.30; P = 0.003), pulmonary (r = 0.43; P = 0.0001)
and extramuscular disease activity (r = 0.36; P = 0.0001), as well as with creatine phosphokinase (r = 0.27; P = 0.015) and
lactate dehydrogenase (r = 0.37; P = 0.002) or c-reactive protein (CRP) levels (r = 0.24; P = 0.038). Multiple regression
analysis showed significant association between S100A4 serum levels and extramuscular disease activity (β = 0.552;
P = 0.002) in PM patients and with MYOACT (β = 0.557; P = 0.003) and CRP levels (β = 0.391; P = 0.029) in DM patients.
Conclusions: Circulating levels of S100A4 are elevated in patients with myositis and associate with several disease
activity parameters, particularly with extramuscular components. No relation between S100A4 levels and presence of
cancer associated myositis was found.Introduction
Idiopathic inflammatory myopathy is a heterogeneous
group of chronic muscle disorders with main subtypes in-
cluding polymyositis (PM), dermatomyositis (DM), inclu-
sion body myositis and necrotizing myopathy [1]. The
diagnosis of myositis is based on the combination of sym-
metrical muscle weakness accompanied by elevation of
circulating muscle enzymes, characteristic electromyo-
graphy (EMG) and muscle biopsy findings. Extramuscular* Correspondence: senolt@revma.cz
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stated.manifestations of myositis are common and include inter-
stitial lung disease, dysphagia or arthritis, and the presence
of distinctive skin rash in patients with DM [2]. An asso-
ciation of idiopathic inflammatory myopathy with malig-
nancy has been documented in a number of studies [3-5].
However, the molecular link explaining the increased
risk of cancer in myositis patients is still poorly under-
stood [6,7].
S100A4 protein represents an important member of
the S100 family of small calcium-binding proteins [8,9].
Interacting with several target proteins, S100A4 affects a
number of activities, accelerating tumorigenesis and in-
vasion of human cancers. At the molecular and cellular
level, the cancer-promoting properties of S100A4 areal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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and by stimulation of angiogenesis and remodelling of the
extracellular matrix [10-14]. The expression of S100A4
protein correlates with the patient’s prognosis in breast
cancer [15], colorectal cancer [16] and variety of other tu-
mors [10,11]. We and others have recently demonstrated
increased expression of S100A4 at local sites of inflamma-
tion in several chronic inflammatory and autoimmune dis-
eases [17-21], including muscle tissue from patients with
idiopathic inflammatory myopathies [22]. Our results
showed, that in inflamed muscle, the S100A4 protein is
produced mainly by mononuclear cells present in the in-
flammatory infiltrates, by endothelial cells and by regener-
ating muscle fibres [22]. Moreover, we have previously
found increased circulating levels of S100A4 in patients
with rheumatoid arthritis (RA) in comparison with control
individuals and demonstrated a positive correlation bet-
ween S100A4 and disease activity in RA [23].
Based on these findings we have conducted a study in
order to determine the S100A4 serum levels in myositis
patients, to evaluate the association between circulating
S100A4 and myositis disease activity and to assess a
potential role of S100A4 in cancer-associated myositis
(CAM).
Methods
Patients and disease activity assessment
A total of 104 patients with myositis (43 with DM, 39
with PM and 22 with CAM) and 77 healthy controls
were enrolled in the study. Longitudinal serum samples
were available for 11 patients. The interval between the
two blood withdrawals was 9 ± 6 months. Myositis
patients were recruited from a single centre of the
inpatient and outpatient departments of the Institute of
Rheumatology in Prague. The diagnosis of DM and PM
was based on the Bohan and Peter criteria [24,25]. CAM
was defined as cancer occurring within 3 years of the
diagnosis of myositis. All individuals gave informed
consent to participate and the study was approved by
the Ethics Committee of the Institute of Rheumatology
in Prague.
Clinical disease activity was evaluated by the disease ac-
tivity core set measures proposed by International Myositis
Assessment & Clinical Studies Group (IMACS): myositis
disease activity assessment (MYOACT) and physician glo-
bal activity using visual analogue scales (VAS), manual
muscle testing (MMT) and the health assessment ques-
tionnaire (HAQ) [26]. Muscle biopsies performed within
one month from the blood withdrawal were available for
13 patients with PM.
Laboratory measurements
Blood samples were collected from all patients and con-
trol individuals and stored at −80°C until analysis. SerumS100A4 concentrations were measured by an ELISA kit
according to the manufacturer’s protocol (CycLex Co,
Ltd, Ina, Nagano, Japan) as demonstrated elsewhere [23].
The analysis was performed using the ELISA reader
SUNRISE (Tecan, Salzburg, Austria) at a wavelength of
450 nm.
Serum levels of the muscle-associated enzymes crea-
tine phosphokinase (CK) and lactate dehydrogenase
(LD), as well as C-reactive protein (CRP) were measured
by routine laboratory techniques. Myositis specific and
associated autoantibodies were detected by immunopre-
cipitation as described elsewhere [27].
Statistical analyses
The data were described as median (IQR) if variables
were not normally distributed and as mean (SD) if
normally distributed. The Kruskal-Wallis test and cor-
responding post-hoc analysis and Mann-Whitney test
were conducted for comparison between groups. Before
analysis of associations among variables, the data were
first transformed toward normality. Logarithmic trans-
formation was used because all variables were positively
skewed. Pearson’s product-moment correlation coeffi-
cients were calculated to quantify relationships between
disease activity, laboratory markers and S100A4 levels.
All correlations were adjusted for age, body mass index,
and disease duration using the partial correlation tech-
nique. Multiple linear regression analysis was performed
to establish whether specific factors were simultaneously
associated with the S100A4 as a dependent variable.
Covariates included age, sex and disease duration, as well
as laboratory markers (CRP, CK and LD) and disease ac-
tivity measures (MYOACTand its components, extramus-
cular and muscle disease activity, physician global disease
assessment, HAQ and MMT8) were considered as inde-
pendent variables. The appropriate predictors were chosen
using a backward stepwise elimination method. Missing
data were excluded using pairwise deletion. P-values <0.05
were considered statistically significant. A correlation co-
efficient of 0.1 to 0.3 was considered weak, 0.3 to 0.5 was
considered moderate and 0.5 to 1.0 was considered strong
correlation. The analysis was performed using SPSS 17.0
(SPSS, Chicago, IL, USA) and the graphs were pre-
pared using GraphPad Prism (version 5.00 for Windows,
GraphPad Software, San Diego, CA USA, [28]).
Results
Characteristics of patients
The characteristics of myositis patients and healthy con-
trols are summarized in Table 1, and types of cancer in
patients with CAM are given in Table 2. A majority of
patients with CAM had DM (n = 18). Disease duration
ranged from 0 to18 months from diagnosis. Some pa-
tients were treated for specific overlap syndromes,
Table 1 Characteristics and demographic data of patients with idiopathic inflammatory myopathies and healthy
controls
Dermatomyositis (DM) Polymyositis (PM) Cancer-associated
myositis (CAM)
Healthy controls (HC)
Number 43 39 22 77
Gender, female/male 35/8 25/14 20/2 58/19
Age, years 58 (41 to 63) 55 (36 to 60) 64 (59 to 70) 45 (31 to 54)
S100A4, ng/ml 26.7 (11.3 to 47.5) 41.6 (24.2 to 123.1) 28.8 (12.6 to 45.4) 23.8 (14.5 to 33.7)
S100A4, ng/ml in females 26.7 (9.0 to 54.7) 54.2 (25.4 to 115.6) 28.8 (13.0 to 47.5) 22.2 (13.6 to 32.1)
S100A4, ng/ml in males 30.3 (19.5 to 44.8) 41.3 (23.9 to 157.9) 20.3 (5.5 to 35.0) 32.3 (19.9 to 64.6)*
Disease duration, years 2.4 (0.4 to 8.3) 0.9 (0.5 to 3.2) 0.6 (0.2 to 3.6) NA
Biochemical markers
CRP, mg/L 3.3 (1.3 to 9.0) 4.7 (2.2 to 26.1) 8.0 (3.2 to 26.6) NA
CK, ukat/L 2.6 (1.2 to 9.9) 11.6 (2.0 to 29.3) 10.9 (1.5 to 37.1) NA
LD, ukat/L 4.4 (3.5 to 6.4) 7.1 (4.2 to 10.9) 5.2 (2.9 to 6.0) NA
Autoantibodies 6*Mi-2 12*Jo-1; 11*TIF1 NA
4*TIF1, 1*TIF1 + U1RNP 1* Jo-1 + U1RNP; 4*Mi-2
2*NXP2 1*Jo-1 + RNAPI + RNAPII 2*Jo-1, 1*Jo-1 + Ro
3*PM-Scl 2*PM-Scl 1*SAE
3*Jo-1 1*PL7 3*without known aAbs






Muscle weakness 43 39 22 NA
Rash 42 1 16 NA
Mechanic’s hands 18 10 8 NA
Raynaud’s phenomenon 9 10 3 NA
Arthritis 14 14 4 NA
Interstitial lung disease 15 22 5 NA
Cardiac involvement 10 6 3 NA
Dysphagia 21 15 10 NA
Disease activity
MYOACT 0.6 (0.15 to 1.5) 0.7 (0.2 to 1.3) 0.8 (0.5 to 1.8) NA
Constitutional DA, VAS 6 (0 to 18) 8 (0 to 24) 0 (0 to 28.5) NA
Cutaneous DA, VAS) 15 (0 to 30) 0 (0 to 6) 28.5 (0 to 52.8) NA
Skeletal DA, VAS 0 (0 to 0) 0 (0 to 7) 0 (0 to 2) NA
Gastrointestinal DA, VAS 0 (0 to 4) 0 (0to3) 0 (0 to 25.5) NA
Pulmonary DA, VAS 0 (0 to 7) 6.5 (0 to 24.7) 0 (0 to 13) NA
Cardiac DA, VAS 0 (0 to 0) 0 (0 to 0) 0 (0 to 0) NA
Extramuscular DA, VAS 15 (4 to 34) 17 (3.5 to 32.5) 20 (11.5 to 54.5) NA
Muscle DA, VAS 10 (3 to 44) 32 (14 to 53) 37 (5.5 to 68.3) NA
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19.5 (4.5 to 43.7) 30.5 (22.5 to 49.3) 42.5 (13.5 to 52) NA
HAQ 1.0 (0.3 to 1.9) 0.9 (0.5 to 1.3) 1.0 (0.5 to 2.6) NA
MMT8 62 (52 to 74) 71 (63 to 74.5) 56 (50.5 to 69.0) NA
Treatment
Treatment duration, months 13.6 (0.9 to 83.6) 2.0 (0.3 to 72.1) 1.4 (0.0 to 20.6) NA
Daily glucocorticoid dosage,
mg prednisone equivalent
10.0 (2.5 to 40.0) 25.0 (3.8 to 50.0) 6.3 (0.0 to 42.5) NA
Immunosuppressive drugs 11*MTX, 3*Plaquenil,
2* AZA, 2*CyA, 23*no
immunosuppressive drugs





1*MTX + SAS, 4*CyA,
2*Plaquenil, 1*AZA, 15*no
immunosuppressive drugs






at the time of blood




Data are presented as number or median (IQR). *S100A4 serum levels in males versus females, P = 0.025. NA, not applicable; CRP, C-reactive protein; CK, creatinine
phosphokinase; LD, lactate dehydrogenase; aAbs, autoantibodies; MYOACT, myositis disease activity assessment; DA, disease activity; VAS, visual analogue scale;
HAQ, health assessment questionnaire; MMT, manual muscle testing; MTX, methotrexate; AZA, azathioprine; CyA, cyclosporine A; SAS, sulfasalazine.
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matosus (n = 3) and systemic sclerosis (n = 3). Two
patients with immune-mediated necrotizing myopathy
(IMNM) were included in the PM subgroup, as they ful-
filled the Bohan and Peter classification criteria [24,25].
All patients had proximal muscle weakness. Rash was
present in 57%, mechanics hands in 35% and Raynaud’s
phenomenon in 21% of patients. Arthritis was diagnosed
in 31% and dysphagia in 44% of patients. Myositis-
associated interstitial lung disease and cardiac involve-
ment was present in 40% and 18% of patients, respectively.
The anti-TIF1 autoantibodies, known to be associated
with malignancy, were detected in 17 myositis patientsTable 2 Types of cancer in patients with cancer-associated
myositis
Type of cancer Number of patients
Breast cancer 8







Sarcoma on the neck 1
Invasive thymoma 1
Metastatic cancer of unknown origin 1
Information missing 1(5 with DM, 1 with PM and 11 with CAM) [29]. Fifteen
patients were treatment-naive at the time of assessment.
In the 84 patients treated with glucocorticoids at the time
of blood withdrawal, the median dose was 15 mg of pred-
nisone or its equivalent per day ranging from 2.5 to
100 mg per day. Twenty-seven patients received metho-
trexate in addition to glucocorticoids, six patients were
treated with cyclosporine A, three with azathioprine and
two with hydroxychloroquine (one in monotherapy). Four
patients were not treated at the time of blood sample col-
lection, but were on immunosuppressive drugs previously.
Circulating S100A4 is elevated in myositis patients
The levels of serum S100A4 were higher in all myositis
patients than in healthy controls (31.5 (17.4 to 59.5) versus
23.8 (14.5 to 33.7) ng/ml, P <0.05). Patients with PM had
higher serum levels of S100A4 compared to healthy con-
trols (41.6 (24.2 to 123.1) versus 23.8 (14.5 to 33.7) ng/ml,
P <0.001) or to patients with DM (to 26.7 (11.3 to 47.5)
ng/ml, P <0.05). There was not a significant difference
between patients with DM or CAM and healthy controls
(26.7 (11.3 to 47.5) or 28.8 (12.6 to 45.4) versus 23.8 (14.5
to 33.7) ng/ml, both P <0.05) (Figure 1).
The levels of serum S100A4 were higher in healthy
male compared to female subjects, but there were no
significant sex-related differences in S100A4 levels in
myositis patients (Table 1). A weak inverse correlation
between S100A4 levels and disease duration was
observed in all myositis patients (r = −0.27; P = 0.006).
In this context, patients who were treated for longer
than 6 months (n = 50) compared with those who were
treated for a shorter period of time (n = 54) had lower
Figure 1 Circulating S100A4 levels in patients with polymyositis
(PM), dermatomyositis (DM), cancer-associated myositis (CAM)
and healthy controls (HC). Horizontal lines represent the median. The
Mann-Whitney U-test was used to calculate P-values for differences
between groups.
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to 65.2) ng/ml, P = 0.002). However, serum levels of
S100A4 did not correlate with daily dose of prednisone
and were not affected by age. In addition, in longitudinal
serum samples S100A4 levels decreased during the treat-
ment; however, due to the limited number of samples
for investigation (n = 11), this change was not statisti-
cally significant (86.4 (40.0 to 218.4) versus 45.2 (28.9 to
139.9) ng/ml, P = 0.195).
Association between S100A4 levels and myositis-specific
and associated autoantibodies
Serum levels of S100A4 were compared between patients
positive or negative for the myositis-specific and asso-
ciated autoantibodies directed against Jo-1, Mi-2, PM-Scl
and TIF1 antigens (Figure 2). Other autoantibodies were
rare and did not allow statistical comparisons. Anti-PM-
Scl-positive patients (n = 5) had significantly higher levels
of S100A4 compared to anti-PM-Scl-negative patients
(n = 99) (98.1 (60.7 to 206.3) versus 30.3 (16.4 to 56.3)
ng/ml, P = 0.008), and similarly, albeit with a smaller
difference, anti-Jo-1-positive patients (n = 25) had higher
S100A4 levels than anti-Jo-1-negative patients (n = 79)
(38.0 (29.1 to 120.6) versus 28.5 (12.1 to 57.2) ng/ml,
P = 0.038). No difference was observed between anti-Mi-
2-positive (n = 10) and -negative (n = 94) patients (32.4
(8.5 to 48.9) versus 31.5 (18.4 to 61.3) ng/ml, p = 0.440).
Surprisingly, anti-TIF1-positive myositis patients (n = 17),
who are more likely to develop cancer, had lower levels of
S100A4 than anti-TIF1-negative ones (n = 87) (17.1 (11.3
to 25.1) versus 36.6 (21.8 to 66.7) ng/ml, P = 0.001).Association between S100A4 levels and myositis disease
activity
Increased serum levels of S100A4 were associated with
several measures of disease activity in myositis patients
overall (Figure 3). Specifically, we found a moderate cor-
relation of S100A4 serum levels with the MYOACT score
(r = 0.34; P = 0.001), constitutional (r = 0.30; P = 0.003),
extramuscular (r = 0.36; P = 0.0001) and pulmonary
disease activity (r = 0.43; P = 0.0001), but not with skeletal
disease activity (r = 0.13; P =0.208). In addition, there
was a weak correlation of S100A4 with CRP (r = 0.24;
P = 0.038) as well as with CK (r = 0.27; P = 0.015) and
moderate correlation with LD (r = 0.37; P = 0.002) serum
levels. On the other side, there was no difference in
S100A4 levels between myositis patients with (n = 32) and
without (n = 72) arthritis (32.3 (17 to 65) versus 31.5
(17 to 58) ng/ml, P = 0.890).
In patients with PM, S100A4 serum levels moderately
correlated with MYOACT (r = 0.43; P = 0.010) and with
constitutional (r = 0.43; P = 0.011), pulmonary (r = 0.44;
P = 0.008), and extramuscular disease activity (r = 0.50;
P = 0.003). Additional multiple correlations are given
online in Additional file 1: Table S1. There was no
correlation of S100A4 serum levels with the degree of
endomysial inflammatory infiltrate and/or MHC-I overex-
pression in the muscle biopsies from patients with PM
(data not shown). No association was demonstrated bet-
ween S100A4 and CK (r = 0.33; P = 0.064), LD (r = 0.36;
P = 0.061), and CRP (r = 0.26; P = 0.169) serum levels in
PM patients.
In patients with DM, S100A4 serum levels correlated
moderately with MYOACT (r = 0.46; P = 0.004) and
pulmonary disease activity (r = 0.41; P = 0.011). Significant
correlations were found between S100A4 and CRP levels
(r = 0.38; P = 0.041), but not CK (r = 0.09; P = 0.631) or
LD (r = 0.19; P = 0.365) serum levels. In addition, we have
not observed any significant correlations between S100A4
serum levels and myositis disease activity or laboratory
markers in patients with cancer-associated myositis (data
not shown).
Multiple regression analysis revealed significant as-
sociation between S100A4 serum levels, pulmonary
disease activity (β = 0.369; P = 0.002), LD (β = 0.345;
P = 0.005) and severity of dysphagia (β = −0.250;
P = 0.033) in the whole myositis patient group. When
analysing the group of PM patients, S100A4 levels were
associated only with extramuscular global assessment
(β = 0.552; P = 0.002), while in the group of DM
patients, S100A4 levels correlated with MYOACT
(β = 0.557; P = 0.003) and CRP (β = 0.391; P = 0.029).
The group of patients with cancer-associated myositis
was too small to perform multiple linear regression ana-
lysis. Furthermore, there were no significant bivariate
correlations within this group.
Figure 2 S100A4 levels in myositis patients divided into two groups based on positive (+) or negative (−) myositis-specific and associated
autoantibodies. (a) Anti-PM-Scl; (b) anti-Jo-1; (c) anti-Mi-2, (d) anti-TIF1 antibodies. Horizontal lines represent the median. The Mann-Whitney U-test
was used to calculate P-values for differences between groups.
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In this study we demonstrated 1) no relationship between
S100A4 and cancer-associated myositis; 2) increased
S100A4 serum levels in myositis patients; 3) a relationship
between S100A4 and some myositis-specific and myositis-
associated autoantibodies; and 4) association between
S100A4 levels and several features of myositis disease ac-
tivity, particularly with extramuscular symptoms.
There is a body of evidence that S100A4 protein is
associated with the development of several cancers and
particularly with their ability to metastasize [11,12,14].
Given the association of myositis, and dermatomyositis
in particular, with increased risk of cancer development
[6,7], it may be surprising that we have not observedFigure 3 Correlations of circulating S100A4 levels with myositis disease
and pulmonary disease activity. DA, disease activity; VAS, visual analogue shigher serum levels of S100A4 in patients with cancer-
associated myositis and that S100A4 levels were even
lower in those with anti-TIF1 autoantibodies, a bio-
marker that identifies a large proportion of myositis
patients with concomitant cancer [30]. We can speculate
that either there was S100A4 consumption in cancer tis-
sue or inability to detect enhanced formation of S100A4
multimeric forms that occur during malignancy [18,31].
Although S100A4 protein was initially studied in ma-
lignancy [10], there are several reports demonstrating
increased amounts of S100A4 in patients with various
inflammatory and autoimmune diseases [17,19-21,32]. In
addition, we have previously demonstrated that S100A4
is expressed mainly by infiltrating mononuclear cells,activity (MYOACT) assessment and its components, constitutional
cale.
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myositis [22]. In this study, we found increased S100A4
serum levels in all myositis patients and particularly in
PM patients compared to those with DM and healthy
individuals. Thus, we suggest that S100A4 may either
reflect diverse pathological processes that occur in dif-
ferent myositis subtypes and/or that it plays a more
important role in PM than in DM.
Furthermore, there was a relationship between circu-
lating S100A4 and the presence of several autoanti-
bodies. We found that the levels of S1004 are elevated in
myositis patients positive for PM-Scl and anti-Jo-1, but
not Mi-2 antibodies. Both arthralgia and non-erosive
arthritis are common in myositis patients, especially in
patients with anti-synthetase autoantibodies such as
anti-Jo-1 [33]. As disease activity in patients with RA
correlated with S100A4 levels [18,23] and anti-Jo-1-posi-
tive patients had increased S100A4 serum levels, we
expected that presence of arthritis would contribute to
the elevation of S100A4 in myositis patients. However,
S100A4 levels were comparable between myositis
patients with and without arthritis, which may point to a
different pathogenesis of joint involvement in myositis
patients compared to those with RA. Thus, it can be
hypothesised that in myositis, S100A4 may be associated
with systemic activation of the immune system rather
than with mechanisms driving arthritis during this
debilitating disease.
In our present study, we demonstrated weak to mo-
derate correlation between S100A4 serum levels and
various myositis disease-activity measures; on the other
side, we found no association between serum S100A4
protein levels and muscle strength or changes in the
muscle biopsy. These results may be consistent with the
findings showing that muscle fibres do not significantly
contribute to S100A4 production and myocytes do not
respond to stimulation with S100A4 protein by pro-
duction of pro-inflammatory cytokines [22,34]. Thus, we
can speculate that circulating S100A4 protein may re-
flect the global disease activity, including extramuscular
organ involvement, rather than functional muscle im-
pairment in inflammatory myopathy. In this context, as-
sociation between S100A4 levels and pulmonary disease
activity may be of clinical significance. However, these
results should be confirmed in further targeted studies.
Conclusion
In summary, we have demonstrated that circulating
S100A4 levels are elevated in myositis patients, espe-
cially in those with polymyositis, and correlate with se-
veral features of myositis disease activity, particularly
with extramuscular involvement, but not with the pres-
ence of cancer. Further studies evaluating the role of
S100A4 in myositis are needed.Additional file
Additional file 1: Multiple correlations.
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